WA People
BILL · 2021–22 SESSION · LATEST VERSION ESHB 1689

HB 1689: Biomarker testing prior auth

Exempting biomarker testing from prior authorization for patients with late stage cancer.

Summary

  • Requires health plans to exempt enrollees from prior authorization requirements for biomarker testing for stage 3 or 4 cancer or recurrent, relapsed, refractory, or metastatic cancer.

From the Engrossed Substitute House Bill Report (ESHB 1689), written by the Legislature's nonpartisan staff. Read the full report ↗

Enacted Enacted · Chapter 123, Laws of 2022
  1. IntroducedJan 10, 2022
  2. Out of committeeJan 27, 2022
  3. Passed HouseFeb 8, 2022
  4. Passed SenateMar 4, 2022
  5. GovernorMar 24, 2022
  6. LawMar 24, 2022
Prime sponsor
Amy Walen (D-48)
Introduced
January 10, 2022 in the House
Last action
March 24, 2022
Session law
Chapter 123, Laws of 2022
Budget
Has a fiscal note
Versions
HB 1689, ESHB 1689

AN ACT Relating to exempting biomarker testing from prior authorization for patients with late stage cancer;

Sponsors

Prime sponsor: Amy Walen (D-48)

7 co-sponsors (5 Democrats, 2 Republicans)

Paul Harris R-17Mari Leavitt D-28Jenny Graham R-6Davina Duerr D-1Lauren Davis D-32Vandana Slatter D-48Steve Tharinger D-24

Votes

House · 3rd Reading & Final Passage

Passed February 8, 2022
Version voted on: ESHB 1689
95 Yea 0 Nay 0 Absent 3 Excused
PartyYeaNayAbsentExcused
Democrat56001
Republican39002
How each member voted

Yea (95)

Excused (3)

Permalink to this vote

Senate · 3rd Reading & Final Passage as Amended by the Senate

Passed March 4, 2022
Version voted on: ESHB 1689
48 Yea 0 Nay 0 Absent 1 Excused
PartyYeaNayAbsentExcused
Democrat28001
Republican20000
How each member voted

Excused (1)

Permalink to this vote

House · Final Passage as Amended by the Senate

Passed March 7, 2022
Version voted on: ESHB 1689
97 Yea 1 Nay 0 Absent 0 Excused
PartyYeaNayAbsentExcused
Democrat57000
Republican40100
How each member voted

Yea (97)

Nay (1)

Permalink to this vote

History

  1. Effective date 6/9/2022. (ESHB 1689)
  2. Chapter 123, 2022 Laws. (ESHB 1689)
  3. Governor signed. (ESHB 1689)
  4. Delivered to Governor. (ESHB 1689)
  5. President signed. (ESHB 1689)
  6. Speaker signed. (ESHB 1689)
  7. Passed final passage; yeas, 97; nays, 1; absent, 0; excused, 0. (ESHB 1689)
  8. House concurred in Senate amendments. (ESHB 1689)
  9. Third reading, passed; yeas, 48; nays, 0; absent, 0; excused, 1. (ESHB 1689)
  10. Rules suspended. Placed on Third Reading. (ESHB 1689)
  11. Committee amendment(s) adopted with no other amendments. (ESHB 1689)
  12. Placed on second reading by Rules Committee. (ESHB 1689)
  13. Passed to Rules Committee for second reading. (ESHB 1689)
  14. Minority; without recommendation. (ESHB 1689)
  15. HLTC - Majority; do pass with amendment(s). (ESHB 1689)
  16. First reading, referred to Health & Long Term Care. (ESHB 1689)
  17. Third reading, passed; yeas, 95; nays, 0; absent, 0; excused, 3. (ESHB 1689)
  18. Rules suspended. Placed on Third Reading. (ESHB 1689)
  19. Floor amendment(s) adopted. (ESHB 1689)
  20. 1st substitute bill substituted. (ESHB 1689)
  21. 1st substitute bill substituted.
  22. Rules Committee relieved of further consideration. Placed on second reading. (ESHB 1689)
  23. Rules Committee relieved of further consideration. Placed on second reading.
  24. Referred to Rules 2 Review. (ESHB 1689)
  25. Referred to Rules 2 Review.
  26. HCW - Majority; 1st substitute bill be substituted, do pass. (ESHB 1689)
  27. HCW - Executive action taken by committee.
  28. HCW - Majority; 1st substitute bill be substituted, do pass.
  29. First reading, referred to Health Care & Wellness.
  30. Prefiled for introduction.

HB 1689 in other sessions

Bill numbers restart every two years, so the same number is a different bill in each session.

Report wrong or missing information on this page